Compare NVRI & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVRI | WVE |
|---|---|---|
| Founded | 1853 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.1M | 673.9M |
| IPO Year | 2026 | 2015 |
| Metric | NVRI | WVE |
|---|---|---|
| Price | $19.39 | $3.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 21 |
| Target Price | ★ $28.67 | $17.00 |
| AVG Volume (30 Days) | 253.4K | ★ 2.9M |
| Earning Date | 11-05-2026 | 10-27-2026 |
| Dividend Yield | ★ 77.72% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | N/A | $47.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $11.15 | $3.04 |
| 52 Week High | $24.20 | $21.73 |
| Indicator | NVRI | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 51.75 |
| Support Level | $18.77 | $3.04 |
| Resistance Level | $19.74 | $4.07 |
| Average True Range (ATR) | 0.82 | 0.19 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 43.00 | 86.30 |
Enviri Corp provides environmental and operational solutions to the metal and rail industries. It is based in Philadelphia, Pennsylvania, and operates in more than 30 countries. The company leverages industrial expertise to help customers improve operational performance, recover value from byproducts, enhance sustainability, and maintain critical infrastructure. Its divisions are Harsco Environmental and Harsco Rail, which combine deep operational capabilities with technologies and world-wide scale to deliver long-term value for customers, communities, and shareholders.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.